Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on May 29, 2015. The report details the entry into a material definitive agreement involving the sale of equity securities to five investors.
Key Financial Metrics and Transaction Details
- Transaction Type: Sale of Series A Preferred Stock and Warrants.
- Aggregate Proceeds: $375,000.
- Securities Issued:
- 150,000 shares of Series A Preferred Stock.
- Warrants to purchase 30,000 shares of common stock.
- Purchase Price: $2.50 per share of Series A Preferred Stock.
- Warrant Exercise Price: $5.00 per share.
- Warrant Term: Five years.
- Dividends: Series A Preferred Stock holders are not entitled to receive dividends.
Material Changes and Terms
The filing discloses a new capital raise event. Key terms regarding the Series A Preferred Stock include:
- Conversion Price: The lower of (i) the price per share of an Acquisition or Next Equity Financing (minimum $1,000,000) closed before October 1, 2015, or (ii) $2.50 if the price is higher or no such event occurs by the deadline.
- Automatic Conversion: Shares automatically convert to common stock immediately prior to an Acquisition or Next Equity Financing (if closed before October 1, 2015) or on October 1, 2015.
- Registration Rights: Investors have the right to request inclusion of underlying shares in future SEC registration statements.
The filing does not provide comparative financial data (revenue, profit, cash flow, or debt) as this is a current report on a specific transaction, not a periodic financial statement.
Guidance, Risks, and Unusual Items
- Regulatory Exemption: The securities were issued pursuant to Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D. Investors represented they are accredited investors acquiring securities for investment purposes only.
- Future Financing Trigger: The conversion mechanics are tied to a potential "Next Equity Financing" of at least $1,000,000 or an acquisition by October 1, 2015.
- Management Commentary: No specific outlook or guidance regarding future operations or financial performance is provided in this filing.
Investor Verification Checklist
- Verify the full text of the Certificate of Designation (Exhibit 3.1) and Securities Purchase Agreement (Exhibit 10.1) for complete rights and preferences.
- Confirm the company's current cash position post-transaction to assess runway, as no balance sheet data is included in this 8-K.
- Monitor for any "Next Equity Financing" or Acquisition announcements prior to the October 1, 2015 deadline to understand the conversion price impact.
- Review the company's recent 10-K or 10-Q filings for historical financial performance and debt obligations not covered in this transaction report.